Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy

被引：4

作者：

Tantry, Udaya ^{[1
]}

Cummings, Charles ^{[1
]}

Mackrell, Peter ^{[1
]}

Gonze, Mark ^{[1
]}

Ulloa, Kristian ^{[1
]}

Bafford, Richard ^{[1
]}

Rout, Amit ^{[1
]}

Sukhi, Ajaypaul ^{[1
]}

Gurbel, Paul ^{[1
]}

机构：

[1] Sinai Hosp Baltimore, Sinai Ctr Thrombosis Res, Baltimore, MD 21215 USA

来源：

FUTURE CARDIOLOGY | 2020年 / 16卷 / 02期

基金：

美国国家卫生研究院;

关键词：

bleeding; coagulation; coronary artery disease; FXa inhibitor; inflammation; peripheral artery disease; platelet; platelet aggregation; FACTOR-XA; DOUBLE-BLIND; GEMINI-ACS-1; ANTIPLATELET; CLOPIDOGREL; OUTCOMES;

D O I：

10.2217/fca-2019-0091

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

COMPASS study demonstrated efficacy of dual pathway inhibition with 2.5 mg twice daily rivaroxaban and aspirin in patients with polyvascular disease (coronary artery disease, peripheral arterial disease or both), the underlying mechanism of which is not clearly understood. In this Phase IV, prospective, open-label and randomized study, we hypothesize that treatment with rivaroxaban is associated with a reduction in platelet activation and aggregation, inflammation and coagulation markers. 30 patients will be randomly treated with aspirin (81 mg q.d.) or aspirin plus rivaroxaban (2.5 mg b.i.d.) for 12 weeks. Platelet aggregation, platelet activation and inflammation markers, thrombin generation kinetics and tissue factor-induced platelet-fibrin clot strength will be measured at baseline, and 4 and 12 weeks after randomization.

引用

页码：69 / 75

页数：7

共 24 条

[1] Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial [J].

Anand, Sonia S. ;

Bosch, Jackie ;

Eikelboom, John W. ;

Connolly, Stuart J. ;

Diaz, Rafael ;

Widimsky, Peter ;

Aboyans, Victor ;

Alings, Marco ;

Kakkar, Ajay K. ;

Keltai, Katalin ;

Maggioni, Aldo P. ;

Lewis, Basil S. ;

Stoerk, Stefan ;

Zhu, Jun ;

Lopez-Jaramillo, Patricio ;

O'Donnell, Martin ;

Commerford, Patrick J. ;

Vinereanu, Dragos ;

Pogosova, Nana ;

Ryden, Lars ;

Fox, Keith A. A. ;

Bhatt, Deepak L. ;

Misselwitz, Frank ;

Varigos, John D. ;

Vanassche, Thomas ;

Avezum, Alvaro A. ;

Chen, Edmond ;

Branch, Kelley ;

Leong, Darryl P. ;

Bangdiwala, Shrikant I. ;

Hart, Robert G. ;

Yusuf, Salim .

LANCET, 2018, 391 (10117) :219-229

[2] Oral anticoagulants in patients with coronary artery disease [J].

Anand, SS ;

Yusuf, S .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (04) :62S-69S

[3]

Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000746, 10.1161/CIR.0000000000000659]

[4] Factor Xa: at the crossroads between coagulation and signaling in physiology and disease [J].

Borensztajn, Keren ;

Peppelenbosch, Maikel P. ;

Spek, C. Arnold .

TRENDS IN MOLECULAR MEDICINE, 2008, 14 (10) :429-440

[5] Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes -: Implications in acute myocardial infarction [J].

Busch, G ;

Seitz, I ;

Steppich, B ;

Hess, S ;

Eckl, R ;

Schömig, A ;

Ott, I .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (02) :461-466

[6] Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease [J].

Eikelboom, J. W. ;

Connolly, S. J. ;

Bosch, J. ;

Dagenais, G. R. ;

Hart, R. G. ;

Shestakovska, O. ;

Diaz, R. ;

Alings, M. ;

Lonn, E. M. ;

Anand, S. S. ;

Widimsky, P. ;

Hori, M. ;

Avezum, A. ;

Piegas, L. S. ;

Branch, K. R. H. ;

Probstfield, J. ;

Bhatt, D. L. ;

Zhu, J. ;

Liang, Y. ;

Maggioni, A. P. ;

Lopez-Jaramillo, P. ;

O'Donnell, M. ;

Kakkar, A. K. ;

Fox, K. A. A. ;

Parkhomenko, A. N. ;

Ertl, G. ;

Stoerk, S. ;

Keltai, M. ;

Ryden, L. ;

Pogosova, N. ;

Dans, A. L. ;

Lanas, F. ;

Commerford, P. J. ;

Torp-Pedersen, C. ;

Guzik, T. J. ;

Verhamme, P. B. ;

Vinereanu, D. ;

Kim, J. -H. ;

Tonkin, A. M. ;

Lewis, B. S. ;

Felix, C. ;

Yusoff, K. ;

Steg, P. G. ;

Metsarinne, K. P. ;

Bruns, N. Cook ;

Misselwitz, F. ;

Chen, E. ;

Leong, D. ;

Yusuf, S. ;

Aboyans, V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (14) :1319-1330

[7]

FDA, 2018, XARELTO PRESCR INF

[8]

Fowkes FGR, 2008, JAMA-J AM MED ASSOC, V300, P197, DOI 10.1001/jama.300.2.197

[9] Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease Focus on the COMPASS Trial [J].

Gurbel, Paul A. ;

Fox, Keith A. A. ;

Tantry, Udaya S. ;

ten Cate, Hugo ;

Weitz, Jeffrey, I .

CIRCULATION, 2019, 139 (18) :2170-2185

[10] GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes [J].

Gurbel, Paul A. ;

Tantry, Udaya S. .

LANCET, 2017, 389 (10081) :1773-1775

← 1 2 3 →